Granata Vincenza, Fusco Roberta, Maio Francesca, Avallone Antonio, Nasti Guglielmo, Palaia Raffaele, Albino Vittorio, Grassi Roberto, Izzo Francesco, Petrillo Antonella
Division of Radiology, ISTITUTO NAZIONALE TUMORI - IRCCS - FONDAZIONE G. PASCALE, NAPOLI, ITALIA, Naples, Italy.
2Division of Radiology, Università degli Studi di Napoli Federico II, Naples, Italy.
Infect Agent Cancer. 2019 Nov 27;14:40. doi: 10.1186/s13027-019-0264-3. eCollection 2019.
To compare liver-specific EOB-GD-DTPA and liver-non-specific Gd-BT-DO3A MR, in hepatocellular carcinoma (HCC) and liver colorectal metastases.
Seventy HCC patients with 158 nodules and 90 colorectal liver metastases (mCRC) with 370 lesions were included in the retrospective analysis. HCC patients underwent MR at 0 time (MR0), after 3 (MR3) and 6 months (MR6) using two different CM; 69 mCRC patients underwent MR with Gd-EOB-BTPA and 21 mCRC patients with Gd-BT-DO3A. We evaluated arterial phase hyperenhancement, lesion-to-liver contrast during portal phase, hepatobiliary phase parenchymal hyperenhancement.
In HCC patients arterial phase hyperenhancement degree was statistically higher ( = 0.03) with Gd-BT-DO3A (mean 4) than GD-EOB-DTPA (mean 2.6), while we found no significant statistical differences among mean (2.6) values at MR0 and MR6 using GD-EOB-DTPA. For all 209 patients underwent Gd-EOB-DTPA, we found that lesion-to-liver contrast during portal phase mean value was 4 while for patients underwent MR with Gd-BT-DO3A was 3 ( = 0.04). For HCC hepatobiliary phase parenchymal hyperenhancement mean value was 2.4. For mCRC patients: among 63 patients underwent previous chemotherapy hepatobiliary phase parenchymal hyperenhancement mean value was 3.1 while for 6 patients no underwent previous chemotherapy was 4 ( = 0.05).
Gd-EOB-DTPA should be chosen in pre surgical setting in patients with colorectal liver metastases.
比较肝细胞癌（HCC）和肝结肠转移瘤中肝脏特异性EOB - GD - DTPA和肝脏非特异性Gd - BT - DO3A磁共振成像（MR）。
回顾性分析纳入70例患有158个结节的HCC患者和90例患有370个病灶的结肠肝转移瘤（mCRC）患者。HCC患者在0时（MR0）、3个月后（MR3）和6个月时（MR6）使用两种不同的对比剂进行MR检查；69例mCRC患者使用Gd - EOB - BTPA进行MR检查，21例mCRC患者使用Gd - BT - DO3A进行MR检查。我们评估了动脉期高增强、门静脉期病灶与肝脏的对比、肝胆期实质高增强情况。
在HCC患者中，使用Gd - BT - DO3A时动脉期高增强程度在统计学上更高（P = 0.03）（平均值为4），高于GD - EOB - DTPA（平均值为2.6），而在使用GD - EOB - DTPA时，我们发现在MR0和MR6时平均值（2.6）之间无显著统计学差异。对于所有209例接受Gd - EOB - DTPA检查的患者，我们发现门静脉期病灶与肝脏对比的平均值为4，而对于接受Gd - BT - DO3A MR检查的患者为3（P = 0.04）。对于HCC，肝胆期实质高增强平均值为2.4。对于mCRC患者：在63例先前接受过化疗的患者中，肝胆期实质高增强平均值为3.1，而在6例未接受过先前化疗的患者中为4（P = 0.05）。
对于结肠肝转移瘤患者，在术前应选择Gd - EOB - DTPA。
